Giant gastric gastrointestinal stromal tumor: A case report.

INTRODUCTION AND IMPORTANCE Gastrointestinal stromal tumor is the most common mesenchymal tumor of the digestive tract. With occurrence in <5 % of all gastrointestinal tract tumors, they encompass 60 % of all gastric stromal tumors. CASE PRESENTATION A 60-year-old man presented to the emergency department with pain abdomen and lump for the past 4 months. Contrast enhanced computed tomography (CECT) abdomen showed a large (largest dimension-25 cm), well-defined, soft tissue lesion on left side of abdominal cavity, crossing the midline to the right side. En-bloc tumor resection with wedge resection of the gastric body was performed. On histopathological examination, definitive diagnosis of giant gastric gastrointestinal stromal tumor (GIST) was established. Postoperatively, the patient received adjuvant oral Imatinib therapy, and is recurrence free at 3-years of follow-up. CLINICAL DISCUSSION The clinical manifestations of GIST are non-specific and vary from being asymptomatic to several signs and symptoms such as abdominal pain, a palpable mass, bleeding, intestinal occlusion, and perforation. Surgical resection is the treatment of choice for GISTs, and neoadjuvant imatinib mesylate therapy for locally advanced GISTs confers good prognosis. CONCLUSIONS Despite the fact that luminal bleeding is the most common presentation, sometimes the tumor may grow exophytically without any symptoms. If large enough as observed in the present case, they may present to emergency department as intra-tumoral bleed. Surgical resection and neoadjuvant therapy with imatinib is equally advantageous even for giant GIST. Diagnosis and therapeutical protocol of GISTs should be established by a trans-disciplinary team.

• Publication year

  2025

• Venue

  International journal of surgery case reports

• Publication date

  2025-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijscr.2025.111420PMID 40393363PMCID PMC12145994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines

  2023cited by this paper
• Giant gastric gastrointestinal stromal tumor with severe peritoneal dissemination controlled by imatinib therapy following debulking surgery: a case report

  2017cited by this paper
• Exophytic gastrointestinal stromal tumor with cystic changes: A case report

  2014cited by this paper
• Gastrointestinal stromal tumor (GIST) mistaken for pancreatic pseudocyst – case report and literature review

  2014cited by this paper
• Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience

  2013cited by this paper
• Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate.

  2013cited by this paper
• [Clinicopathological features and prognosis of cystic gastrointestinal stromal tumor].

  2011cited by this paper
• Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

  2009cited by this paper
• Gastrointestinal stromal tumors: review on morphology, diagnosis and management.

  2009cited by this paper
• Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.

  2009cited by this paper
• [Gastric stromal tumors--Clinical and histopathological analysis of four cases].

  2003cited by this paper
• Gastrointestinal stromal tumors: radiologic features with pathologic correlation.

  2003cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper

• No citing papers are available for this paper.